US FDA Moves Homeopathic Drug Enforcement To Risk-Based Approach
This article was originally published in The Pink Sheet
Executive Summary
Products with routes of administration other than oral and topical or intended to be used for the prevention or treatment of serious or life-threatening diseases and conditions will be among those prioritized for enforcement and "regulatory actions," draft guidance notes.
You may also be interested in...
FTC Homeopathic Disclaimer Policy Should Prompt FDA Changes – Advocacy Group
Center for Inquiry reiterates its criticism of homeopathy and calls on FDA to step up vetting of US-marketed homeopathic products.
OTC Homeopathic Labels Must Include Scientific Disclaimers – FTC
US trade regulator will require an "inherent contradiction" for homeopathic OTC labels: disclaimers to FDA-compliant label indications indicating a lack of scientific evidence that the product works.
FDA Examination Of Homeopathic Regulation Looks Beyond Safety History
CDER Director Janet Woodcock says the current regulatory framework limits FDA’s direct regulation of homeopathics to post-market surveillance. During a two-day public hearing, agency officials question stakeholders about trials, labeling and how well consumers understand their products.